Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program

PURPOSE/BACKGROUND: The Phase 3 program for RBP-7000, a once-monthly subcutaneous (SC) extended-release risperidone formulation approved for treatment of schizophrenia, consisted of a double-blind placebo-controlled trial (previously reported) and a 52-week open-label study of monthly RBP-7000 120 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Andorn, Anne, Graham, Jay, Csernansky, John, Newcomer, John W., Shinde, Sunita, Muma, Gilbert, Heidbreder, Christian, Fava, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728056/
https://www.ncbi.nlm.nih.gov/pubmed/31343440
http://dx.doi.org/10.1097/JCP.0000000000001076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728056/
https://www.ncbi.nlm.nih.gov/pubmed/31343440
http://dx.doi.org/10.1097/JCP.0000000000001076

Ejemplares similares